A Multi-Center, Randomized, Double Blind, Placebo Controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Lacosamide (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Schwarz Pharma AG; UCB
- 20 Feb 2009 Primary endpoint 'Headache frequency' has not been met.
- 26 Jul 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov
- 15 Feb 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov.